Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside
Portfolio Pulse from Vandana Singh
Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ:PHVS) with an Outperform rating and a price target of $27. The analyst sees a 35% upside potential and highlights Pharvaris' strategy to develop oral therapeutic options for hereditary angioedema (HAE). The analyst's estimates are skewed toward PHVS416, an acute HAE therapy, with a projected launch by FY26 and FY30 revenue reaching $644 million. The clinical hold on the PHVS719 program is expected to be lifted, allowing for advancement to the prophylactic market.
September 25, 2023 | 7:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharvaris N.V. has received an Outperform rating from Wedbush with a price target of $27, indicating a 35% upside. The company's focus on developing oral therapeutic options for HAE, particularly PHVS416 and PHVS719, is highlighted.
The positive coverage from Wedbush, along with the Outperform rating and the $27 price target, indicates a bullish outlook for Pharvaris. The company's focus on developing oral therapeutic options for HAE, particularly PHVS416 and PHVS719, is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100